What's Happening?
Goldman Sachs has revised its net profit forecasts for Shanghai Pharmaceuticals for 2026-2027, increasing them by 5.8% and 1.7% respectively. This adjustment reflects higher selling expenses and the consolidation of Shanghai Hutchison Pharmaceuticals.
Despite a 4.4% year-over-year increase in revenue for the fourth quarter of 2025, reaching RMB68.5 billion, the net profit was RMB578 million, which is below the broker's estimation of RMB1.2 billion. The discrepancy is attributed to increased selling expenses due to the commercialization of innovative drugs, as well as investment losses and asset impairments. Goldman Sachs has also introduced a 2028 EPS forecast of RMB1.06 and raised its target price for Shanghai Pharmaceuticals from HKD10.03 to HKD10.3, maintaining a 'Sell' rating.
Why It's Important?
The adjustments made by Goldman Sachs highlight the financial challenges faced by Shanghai Pharmaceuticals, particularly in managing selling expenses and investment losses. The company's performance is crucial for investors and stakeholders, as it impacts market confidence and investment decisions. The increase in selling expenses due to drug commercialization indicates a strategic focus on innovation, which could drive future growth. However, the lower-than-expected net profit underscores the need for effective cost management and strategic planning. The revised forecasts and target price reflect Goldman Sachs' assessment of the company's financial health and market position.
